Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelial KLF4 depletion drives age-related neurovascular dysfunction and neuropsychiatric impairment.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration.

Acta neuropathologica·2026
Same author

Data-driven thresholds for standardized classification of severe Alzheimer's disease neuropathology using digital neuropathology.

Brain pathology (Zurich, Switzerland)·2026
Same author

Vascular burden attenuates the TDP-43-TMEM106B pathological relationship in neurodegenerative disease with and without Alzheimer disease neuropathological change.

Journal of neuropathology and experimental neurology·2026
Same author

Modeling small vessel disease burden and vascular dementia likelihood from NACC data.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Examining neuroimaging biomarkers, plasma biomarkers and cognitive functions in patients with recovered COVID-19 infection: a multicentre study using 7T MRI.

Brain communications·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Julie Parker-Garza1, Tiffany F Kautz2, Sudha Seshadri3

  • 1Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

Clinical Laboratory Improvement Amendments (CLIA) approval was achieved for the Fujirebio Lumipulse amyloid-beta (AB) 42:40 assay. This ensures accurate Alzheimer's disease (AD) biomarker results for clinical diagnosis and personalized medicine.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Clinical diagnostics
  • Biomarker assay validation
  • Alzheimer's disease research

Background:

  • Clinical Laboratory Improvement Amendments (CLIA) are vital for regulating laboratory testing accuracy and reliability.
  • Alzheimer's disease (AD) biomarkers are crucial for early detection, diagnosis, and treatment, requiring CLIA approval for clinical integration.
  • The Fujirebio Lumipulse amyloid-beta (AB) 42:40 cerebral spinal fluid (CSF) assay recently received FDA approval, necessitating CLIA certification for clinical use.

Purpose of the Study:

  • To detail the process and requirements for obtaining Clinical Laboratory Improvement Amendments (CLIA) approval for Alzheimer's disease (AD) biomarkers.
  • To explain the specific steps and validation needed for the Fujirebio Lumipulse AB 42:40 CSF assay to meet CLIA certification standards.
  • To demonstrate the successful attainment of CLIA certification for a novel AD biomarker assay.

Main Methods:

  • Reviewed Clinical Laboratory Improvement Amendments (CLIA) processes for Alzheimer's disease (AD) biomarkers.
  • Executed validation protocols for the AB 42:40 ratio in CSF using the Lumipulse G1200 analyzer.
  • Ensured compliance with CLIA staffing, monitoring, and documentation for a Certificate of Compliance, using biobank CSF across two laboratory settings for blinded technician assessment.

Main Results:

  • Achieved Clinical Laboratory Improvement Amendments (CLIA) certification for the Fujirebio AD biomarker test by meeting accuracy, reproducibility, and clinical utility requirements.
  • Demonstrated high correlation (R2=0.9819) in validation testing between two distinct laboratory sites, confirming test reliability.
  • Successfully met all criteria for CLIA certification, paving the way for clinical integration of the AB 42:40 CSF assay.

Conclusions:

  • CLIA certification enables the return of Fujirebio Lumipulse AB 42:40 biomarker results for clinical diagnosis and research in Alzheimer's disease (AD).
  • CLIA approval confirms consistent performance of biomarker assays across clinical settings and patient populations, validating the Fujirebio CSF AB42:40 test.
  • Clinical Laboratory Improvement Amendments (CLIA) approval is essential for making AD biomarkers accessible for routine clinical application, precision medicine, and early intervention strategies.